Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2025-12-10

Clinical Trial Update: Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating allogeneic ABCB5-positive dermal mesenchymal stromal cells for epidermolysis bullosa; the study is currently active but not re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ABCB5-positive dermal mesenchymal stromal cells (ABCB5-positive dermal mesenchymal stromal cells)

Snippet

Sponsor: RHEACELL GmbH & Co. KG | Conditions: Epidermolysis Bullosa | Phase 3 | Status: ACTIVE_NOT_RECRUITING